Smith Michael David 4
4 · KalVista Pharmaceuticals, Inc. · Filed Apr 30, 2021
Insider Transaction Report
Form 4
Smith Michael David
Sr. VP, Development
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2021-04-28−10,014→ 30,096 totalExercise: $8.39Exp: 2026-11-21→ Common Stock (10,014 underlying) - Exercise/Conversion
Common Stock
2021-04-28$8.39/sh+10,014$84,017→ 10,014 total - Sale
Common Stock
2021-04-28$25.76/sh−10,014$257,983→ 0 total
Footnotes (1)
- [F1]The option is fully vested.